The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC).
 
Earle Frederick Burgess
Stock and Other Ownership Interests - Becton Dickinson; Calithera Biosciences; Exelixis; Gilead Sciences; Ignyta; Johnson & Johnson; McKesson; Medtronic
Consulting or Advisory Role - Bayer; Janssen; Pfizer; Roche/Genentech
Speakers' Bureau - Exelixis; Roche/Genentech
Research Funding - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - Exelixis; Pfizer; Roche/Genentech
 
Claud Grigg
No Relationships to Disclose
 
Peter E Clark
Consulting or Advisory Role - Genentech/Roche
 
Danielle Boselli
No Relationships to Disclose
 
James Thomas Symanowski
Consulting or Advisory Role - Boston Biomedical; Endocyte (Inst); immatics; Lilly; Ra Pharma (Inst)
Research Funding - Bayer (Inst); Celgene (Inst); Novocure (Inst)
 
Derek Raghavan
Consulting or Advisory Role - Caris Life Sciences (Inst); Gerson Lehrman Group